

Prosthetic joint infections - Pipeline Insight, 2021

<https://marketpublishers.com/r/P314AA72B60CEN.html>

Date: July 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P314AA72B60CEN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Prosthetic joint infections - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prosthetic joint infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Prosthetic joint infections Understanding

Prosthetic joint infections: Overview

Prosthetic joint infection (PJI), also referred to as periprosthetic infection, is defined as infection involving the joint prosthesis and adjacent tissue. The clinical manifestations of PJI vary depending upon the virulence of the organism, the mode of initiation of infection, the host immune response, the soft tissue structure surrounding the joint, and the joint involved. The diagnosis of PJI is based upon a combination of clinical findings, laboratory results from peripheral blood and synovial fluid, microbiological data, histological evaluation of periprosthetic tissue, intraoperative inspection, and/or radiographic results. Treatment for PJI involves surgical intervention and medical therapy with an aim to eradicate the infection, restore pain-free function of the infected joint, and minimize PJI-related morbidity and mortality for the patient.

'Prosthetic joint infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Prosthetic joint infections pipeline landscape is provided which includes the disease overview and Prosthetic joint infections treatment guidelines. The assessment part of the report embraces, in depth Prosthetic joint infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prosthetic joint infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Prosthetic joint infections R&D. The therapies under development are focused on novel approaches to treat/improve Prosthetic joint infections.

Prosthetic joint infections Emerging Drugs Chapters

This segment of the Prosthetic joint infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Prosthetic joint infections Emerging Drugs

TNP 2092: TenNor Therapeutics

TNP-2092 is a multitargeting drug conjugate, exerting antibacterial activity by inhibiting three essential targets in bacterial biofilms: RNA polymerase, DNA gyrase and topoisomerase IV. TNP-2092 has demonstrated strong bactericidal activity, low frequency for development of resistance and an excellent safety profile. The drug is in Phase II clinical developmental studies for the treatment of bacterial infections; and skin and soft tissue infections. In January 2020, TenNor Therapeutics received FDA Orphan

Drug Designation for TNP-2092 to treat prosthetic joint infections.

PLG0206: Peptilogs

PLG0206 is an intravenous antibiotic derived from cationic antibiotic peptide (eCAP) platform. PLG0206 works by targeting and disrupting bacterial membranes leading to the death of bacterial cells. PLG0206 has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for the treatment of prosthetic joint infections (PJI). The drug has completed Phase I clinical studies for bacterial infections.

Further product details are provided in the report.....

Prosthetic joint infections: Therapeutic Assessment

This segment of the report provides insights about the different Prosthetic joint infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Prosthetic joint infections

There are approx. 5+ key companies which are developing the therapies for Prosthetic joint infections. The companies which have their Prosthetic joint infections drug candidates in the most advanced stage, i.e. Phase II include, TenNor Therapeutics.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Prosthetic joint infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Prosthetic joint infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Prosthetic joint infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prosthetic joint infections drugs.

Prosthetic joint infections Report Insights

- Prosthetic joint infections Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Prosthetic joint infections Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Prosthetic joint infections drugs?

How many Prosthetic joint infections drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prosthetic joint infections?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Prosthetic joint infections therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Prosthetic joint infections and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

TenNor Therapeutics

Peptilogics

Armata Pharmaceuticals

Contrafact

Osteal Therapeutics

Key Products

TNP 2092

PLG0206

AP-SA02

CF-296

VT-X7

Contents

Introduction

Executive Summary

Prosthetic joint infections: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Prosthetic joint infections – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

TNP 2092: TenNor Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

PLG0206: Peptilogics

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
 Comparative Analysis
AP-SA02: Armata Pharmaceuticals
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Prosthetic joint infections Key Companies
Prosthetic joint infections Key Products
Prosthetic joint infections- Unmet Needs
Prosthetic joint infections- Market Drivers and Barriers
Prosthetic joint infections- Future Perspectives and Conclusion
Prosthetic joint infections Analyst Views
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Prosthetic joint infections
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Prosthetic joint infections
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Prosthetic joint infections - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P314AA72B60CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P314AA72B60CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970